With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Now in Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.

Events

Dec 18, 2023 at 5:00 PM EST

Crinetics Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Join Webcast

Sep 26, 2023 at 1:00 PM EDT

Cantor Global Healthcare Conference 2023
Live and archived webcast:

Sep 11, 2023 at 8:00 AM EDT

Crinetics Topline Results from Paltusotine Phase 3 PATHFNDR-1 Study
Join Webcast

Aug 8, 2023 at 12:00 PM EDT

KOL Webinar on Current Treatment Landscape and Unmet Medical Need in Acromegaly
To register for the webinar, please click here:

Press Releases

April 11, 2024

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024 , the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock …

March 19, 2024

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p …

March 12, 2024

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positive Data Previously Reported …
View All Events
View All Press Releases

Corporate Presentation

 

Dive deeper into Crinetics, the market needs we address, our pipeline and candidate drugs, clinical trials, and more.

crinetics

Investor Resources

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact

Contact